Abstract
Introduction: Over 80% of colorectal cancer (CRC) patients treated with anti-EGFR antibodies (cetuximab or panitumumab) suffer from various types of skin toxicity – including acne-like rash, xerosis, paronychia or telangiectasia. The prospective clinical trial phase II (STEPP) proved that the primary prophylaxis with oral doxycycline (200 mg daily), topical steroids and sun blockers was efficacious. To further test the efficacy of systemic doxycycline we planned a single arm phase II prospective study of lower dose doxycycline (100 mg daily orally) in prevention of anti-EGFR skin toxicity in CRC patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
